Poor Magnesium Status Increases Mortality Risk in MASLD and MetALD Patients, reveals research

•v CVD-related mortality was even higher, with a 3.01-fold increase (HR: 3.01; 95% CI: 1.87-4.86; p< 0.0001).

• The association was more potent among those individuals who did not reach the estimated average requirement for magnesium intake (HR: 2.72; 95% CI: 1.69-4.37; p=0.0014).

• Individuals with an FIB-4 index < 1.3 had a significantly higher risk for all-cause mortality, with an HR of 2.95 (95% CI: 1.69-5.15; p=0.0006).

Magnesium is essential for many metabolic functions, such as glucose regulation, cardiovascular health, and liver function. The benefits of magnesium supplementation or dietary interventions aimed at increasing magnesium intake among high-risk patients are highlighted by this study.

The authors of the study concluded that poor magnesium status as reflected by higher MDS is highly associated with greater rates of all-cause and CVD mortality among MASLD and MetALD patients. Addressing the underlying magnesium deficiency in this population using dietary and appropriate supplement interventions may yield long-term health benefits and an improved survival outcome.

Reference:

Fan L, Zhu X, Zhang X, Salvador S, Zhang X, Shrubsole MJ, Izzy MJ, Dai Q. Magnesium Depletion Score and Mortality in Individuals with Metabolic Dysfunction Associated Steatotic Liver Disease over a Median Follow-Up of 26 Years. Nutrients. 2025 Jan 10;17(2):244. doi: 10.3390/nu17020244. PMID: 39861373; PMCID: PMC11767615